Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients.
Zinzani PL, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, Alinari L, Farsad M, Musuraca G, Gabriele A, Marchi E, Nanni C, Canini R, Monetti N, Baccarani M. Zinzani PL, et al. Among authors: baccarani m. Br J Cancer. 2004 Aug 31;91(5):850-4. doi: 10.1038/sj.bjc.6602040. Br J Cancer. 2004. PMID: 15266320 Free PMC article.
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.
Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Bacci F, Pileri S, Baccarani M. Zinzani PL, et al. Among authors: baccarani m. Ann Oncol. 2008 Apr;19(4):769-73. doi: 10.1093/annonc/mdm560. Epub 2008 Feb 25. Ann Oncol. 2008. PMID: 18303033 Free article. Clinical Trial.
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarani M, Tura S. Zinzani PL, et al. Among authors: baccarani m. Ann Oncol. 2002 Sep;13(9):1364-9. doi: 10.1093/annonc/mdf208. Ann Oncol. 2002. PMID: 12196361 Free article. Clinical Trial.
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M. Zinzani PL, et al. Among authors: baccarani m. Ann Oncol. 2012 Feb;23(2):415-20. doi: 10.1093/annonc/mdr145. Epub 2011 May 2. Ann Oncol. 2012. PMID: 21536660 Free article. Clinical Trial.
Hodgkin's disease (HD): a historical perspective.
Tura S, Mazza P, Zinzani PL, Verlicchi F, Baccarani M, Lauria F, Fiacchini M, Gobbi M, Bandini G, Emiliani E, et al. Tura S, et al. Among authors: baccarani m. Eur J Cancer Clin Oncol. 1986 Nov;22(11):1315-23. doi: 10.1016/0277-5379(86)90139-2. Eur J Cancer Clin Oncol. 1986. PMID: 2435555
777 results